EDN1 and chronic obstructive pulmonary disease: The main conclusion of the authors was that “pravastatin significantly improved exercise tolerance, and decreased PH and dyspnoea during exercise, probably by inhibiting ET-1 synthesis in COPD patients with PH (14).